Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

An encapsulation-free oral subunit vaccine for VHSV, Inducing robust antiviral and antibody responses

  • Aceituno Abarzúa, Patricia|||0000-0002-6015-3274
  • Rojas Peña, Mauricio|||0000-0002-2373-1792
  • Salvador, Maria E.|||0000-0002-8877-2018
  • García Ordóñez, Marlid|||0000-0002-0731-0509
  • Chico, Veronica|||0000-0001-6983-2786
  • Ordóñez Grande, Borja|||0000-0002-4705-6867
  • Alarcón-López, Francisco Javier|||0000-0002-7187-6814
  • Perez Garcia-Estañ, Luis|||0000-0003-4078-8763
  • Ortega-Villaizan, Maria del Mar|||0000-0003-2065-0601
  • Roher Armentia, Nerea|||0000-0002-6659-4038
Viral haemorrhagic septicaemia (VHS) is a viral disease that causes high mortality in numerous teleost species, both farmed and wild. A commercial vaccine against the VHS virus is not yet available. Due to the difficulty and stress of early-stage injection, the oral route would undoubtedly be the optimal vaccination route in terms of animal welfare and handling costs. However, oral administration has drawbacks, primarily weak immune protection and vaccine degradation, which in most cases requires additional encapsulation. Here we present a recombinant protein subunit vaccine against VHSV that is highly stable, does not require encapsulation, and stimulates both local and systemic antiviral responses after oral intubation. Additionally, it activates the adaptive immune response, inducing the production of specific and neutralizing antibodies when administered either by intubation or incorporated into fish feed. The vaccine consists of VHSV glycoprotein G fused with an interferon-gamma (IFNγ) domain from Oncorhynchus mykiss, overexpressed in Escherichia coli and purified as a highly structured nanostructured biomaterial (nanopellets, NPs). These NPs were internalized by the rainbow trout intestinal epithelial cell line (RTgutGC) and rainbow trout head kidney macrophage (RT-HKM) cells and were fully functional triggering antiviral and inflammatory gene expression and activating the interferon signaling pathway. To evaluate whether VHSV-IFN could be absorbed in the gut and induce a local and systemic immune response, trout fry were intubated at two doses, 30 mg/kg fish and 125 mg/kg fish. Analysis of hindgut-sorted leukocytes revealed two populations-myeloid and lymphoid-the latter showing a strong antiviral response at the higher dose. Consistent with this, we observed in the head kidney (HK) of fish intubated with VHSV-IFN, a clear antiviral gene response. Interestingly, fish treated with VHSV-IFN at 125 mg/kg fish and 500 mg/kg fish administered by intubation and orally in the diet, respectively, showed an increase in specific and neutralizing antibody titres 30 days after vaccination, demonstrating its ability to induce a robust adaptive response.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

How modular protein nanoparticles may expand the ability of subunit anti-viral vaccines, The spring viremia carp virus (SVCV) case

  • Rojas Peña, Mauricio|||0000-0002-2373-1792
  • Aceituno Abarzúa, Patricia|||0000-0002-6015-3274
  • Salvador, Maria E.|||0000-0002-8877-2018
  • García Ordóñez, Marlid|||0000-0002-0731-0509
  • Teles, Mariana|||0000-0001-5525-4049
  • Ortega-Villaizan, Maria del Mar|||0000-0003-2065-0601
  • Perez, Luis
  • Roher Armentia, Nerea|||0000-0002-6659-4038
Spring viremia of carp (SVC) remains as a vaccine orphan disease mostly affecting juvenile specimens. Young fish are especially difficult to vaccinate and oral administration of vaccine combined with food would be the election system to minimise stress and the vaccination costs associated to injection. However, administration of prophylactics with food pellets faces off several drawbacks mainly related with vaccine degradation and weak protection correlates of oral vaccines. Here we present a platform based on recombinant proteins (subunit vaccines) manufactured as highly resistant nanostructured materials, and providing excellent levels of protection against SVC virus in a preliminary i.p injection challenge. The G3 domain of SVCV glycoprotein G was overexpressed in E. coli together with IFNγ and the modular protein was purified from bacterial aggregates (inclusion bodies) as highly organised nanostructured biomaterial (nanopellets, NP). These SVCV-IFN were taken up by zebrafish cells leading to the enhanced expression of different antiviral and IFN markers (e.g vig1, mx, lmp2 or ifngr1 among others) in zebrafish liver cells (ZFL). To monitor if SVCV and SVCV-IFN can be taken up by intestinal epithelia and can induce antiviral response we performed experiments with SVCV and SVCV-IFN in 3 days post fertilization (dpf) zebrafish larvae. Both, SVCV and SVCV-IFN were taken up and accumulated in the intestine without signs of toxicity. The antiviral response in larvae showed a different induction pattern: SVCV-IFN did not induce an antiviral response while SVCV showed a good antiviral induction. Interestingly ZF4, an embryonic derived cell line, showed an antiviral response like ZFL cells, although the lmp2 and ifngr1 (markers of the IFNγ response) were not overexpressed. Experiments with adult zebrafish indicated an excellent level of protection against a SVCV model infection where SVCV-IFN vaccinated fish reached 20% cumulative mortality while control fish reached over 80% cumulative mortality.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Polystyrene nanoplastics target lysosomes interfering with lipid metabolism through the PPAR system and affecting macrophage functionalization

  • Brandts, Irene|||0000-0002-7372-8639
  • Solà, Roger
  • García Ordóñez, Marlid|||0000-0002-0731-0509
  • Gella, Alejandro|||0000-0002-3983-1392
  • Quintana Romero, Albert|||0000-0003-1674-7160
  • Martin, Beatriz
  • Esteve-Codina, Anna|||0000-0003-0361-2873
  • Teles, Mariana|||0000-0001-5525-4049
  • Roher Armentia, Nerea|||0000-0002-6659-4038
Nanoplastics (NPs) are currently a main concern for environmental, animal and human health due to their potential to accumulate in different environmental compartments and provoke effects in living organisms. Nevertheless, neither these effects nor the interaction of NPs with the cellular machinery are well characterized, and only scattered information is available. In the present work, we focused on the interaction between NPs and fish cells, both intestinal cells and macrophages, in order to understand which cell organelles are targeted by polystyrene (PS)-NPs and how this could impact cell function. PS-NPs can pass through phospholipid membranes, entering cells via endocytosis, phagocytosis or passive transport. Once internalized, we found that PS-NPs co-localize with lysosomes but not with mitochondria. Moreover, using two types of fluorescent probe (HDCFDA and DHE) we demonstrated that NPs did not trigger the production of reactive oxygen species (ROS), which was corroborated by the fact that neither the oxidative consumption ratio (OCR) nor the extracellular acidification rate (ECAR) in mitochondrial respiration were altered. RNASeq data revealed clear interference by PS-NPs with lipid metabolism, peroxisomes and PPAR signaling. The M1/M2 balance critically determines tissue homeostasis when exposed to exogenous agents such as microorganisms or pollutants. Thus, the expression of different genes (il1β, tnfα, il6, il10, il12, cox2, mmp9, ppar a, b and g) was further assessed to characterize the macrophage phenotype M1 or M2, induced by PS-NPs. Overall, in this study we demonstrate that PS-NPs co-localize within lysosomes, both in macrophages and in intestinal cells of rainbow trout, but do not trigger ROS production nor alter mitochondrial respiration. In macrophages, PS-NPs modulate polarization towards the M2-like phenotype.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Efficient Delivery of Antimicrobial Peptides in an Innovative, Slow-Release Pharmacological Formulation

  • Serna, Naroa|||0000-0001-5682-8198
  • López-Laguna, Hèctor|||0000-0001-5249-8304
  • Aceituno Abarzúa, Patricia|||0000-0002-6015-3274
  • Rojas Peña, Mauricio|||0000-0002-2373-1792
  • Parladé, Eloi|||0000-0001-5750-550X
  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Martinez Torro, Carlos|||0000-0002-3529-3355
  • Sánchez, Julieta M.|||0000-0001-6676-5776
  • Di Somma, Angela|||0000-0003-4916-7875
  • Carratalá, José Vicente|||0000-0001-6950-2939
  • Livieri, Andrea L.
  • Ferrer-Miralles, Neus|||0000-0003-2981-3913
  • Vázquez, Esther|||0000-0003-1052-0424
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Roher Armentia, Nerea|||0000-0002-6659-4038
  • Villaverde, Antonio|||0000-0002-2615-4521
Both nanostructure and multivalency enhance the biological activities of antimicrobial peptides (AMPs), whose mechanism of action is cooperative. In addition, the efficacy of a particular AMP should benefit from a steady concentration at the local place of action and, therefore, from a slow release after a dynamic repository. In the context of emerging multi-resistant bacterial infections and the urgent need for novel and effective antimicrobial drugs, we tested these concepts through the engineering of four AMPs into supramolecular complexes as pharmacological entities. For that purpose, GWH1, T22, Pt5, and PaD, produced as GFP or human nidogen-based His-tagged fusion proteins, were engineered as self-assembling oligomeric nanoparticles ranging from 10 to 70 nm and further packaged into nanoparticle-leaking submicron granules. Since these materials slowly release functional nanoparticles during their time-sustained unpacking, they are suitable for use as drug depots in vivo. In this context, a particular AMP version (GWH1-NIDO-H6) was selected for in vivo validation in a zebrafish model of a complex bacterial infection. The GWH1-NIDO-H6-secreting protein granules are protective in zebrafish against infection by the multi-resistant bacterium Stenotrophomonas maltophilia, proving the potential of innovative formulations based on nanostructured and slowly released recombinant AMPs in the fight against bacterial infections.